Navigation Links
Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
Date:2/11/2010

reported by at least 20% of all patients included headache, nasopharyngitis, injury, arthralgia, cough, pyrexia, dizziness, influenza, nasal congestion, vomiting, bone pain, and activated partial thromboplastin time (aPTT) prolonged. No drug-related serious adverse events were reported.  No patient withdrew from the study due to an adverse event. One patient developed antibodies to velaglucerase alfa.  

A subpopulation analysis of study TKT032 was conducted to assess the efficacy and safety of velaglucerase alfa among children aged 2-17. Of 25 patients in the trial, 7 pediatric patients (28%) were enrolled and randomized to receive velaglucerase alfa at 60 U/kg (n=4) or 45 U/kg (n=3) as a 1-hour infusion, every other week for 12 months. In this analysis the two dose groups were pooled and results are shown as a percent change from baseline.

Following 12 months treatment with velaglucerase alfa the mean hemoglobin concentration increased 20%, mean platelet counts increased 54%, mean spleen volume, normalized by body weight, decreased 47% (median value 5.0 multiples of normal (MN) decreased from 13.5 MN). Mean liver volume normalized by body weight decreased 13% (median value 1.04 MN decreased from 1.40 MN). Outcomes reported in children were consistent with those seen in the overall population. Due to the small sample sizes, the results did not achieve statistical significance.

Most frequently reported adverse events in the pediatric subpopulation were headache, nasopharyngitis, pyrexia, nasal congestion, productive cough, vomiting, and injury. No pediatric participants experienced severe or serious treatment-emergent events. No pediatric patients developed antibodies to velaglucerase alfa.

"We are very pleased with the opportunity to present the findings from the first of three Phase III studies for velaglucerase alfa," said Whaijen Soo, MD, PhD, Senior Vice President, Research and Development, Shire Hum
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
2. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
3. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
4. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
5. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
6. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
7. Shire Continues to Deliver Excellent Growth From Core Products
8. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
9. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
10. Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
11. Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 Levi ... been commenced in the United States District Court for ... behalf of investors who purchased Galectin Therapeutics Inc. ("Galectin" ... 2014 and July 28, 2014. For more ... complaint alleges that during the Class Period the Company ...
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, ... leader in noninvasive medical monitoring, today announced that the ... Model 3231 OEM/eHealth finger pulse oximeter for use in ... pulse oximeter plugs into a telemedicine hub or kiosk ... pulse rate in pediatric to adult patients. The Model ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... and Company (NYSE: LLY ) today issued ... and chief executive officer about his meeting today with ... job creation, American innovation and competiveness: "It,s ... and take part in this very important dialogue today ...
... Dec. 15, 2010 Johnson & Johnson (NYSE: ... Worldwide Chairman, Medical Devices & Diagnostics (MD&D) and Sheri ... Chairmen of the Executive Committee and join William C. ... in an expanded Office of the Chairman.  Both appointments ...
Cached Medicine Technology:Lilly Statement Regarding President Obama's Meeting With U.S. Business Leaders 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 2Johnson & Johnson Announces Executive Appointments: Alex Gorsky, Vice Chairman, Executive Committee Sheri McCoy, Vice Chairman, Executive Committee 3
(Date:8/29/2014)... Most dentists work during normal business hours. That ... their day to be able to go see the dentist. ... a few hours during their increasingly busy days. That is ... It is now possible for people to get the preventative ... happening? , North York Dental has realized that it is ...
(Date:8/29/2014)... The Florida Chiropractic Association held its National ... week August 21-24 and Maryland and Virginia chiropractor ... , Dr. Greenstein presented at three different sessions: ... standing room session; (2) A Panelist at the Plenary ... the Way in Injury Prevention and Maximizing Human Performance; ...
(Date:8/29/2014)... Recent reports, backed by the US ... are working longer hours and taking fewer vacations than ... believes that drinking lots of purified water can help, ... their most popular and effective water purification systems to ... 9/2/2014, customers can save up to $125 off all ...
(Date:8/29/2014)... Auckland, NZ (PRWEB) August 29, 2014 ... of Greg Allen to Chief Executive Officer effective from ... Chief Technology Officer for Winscribe. , “During this time ... Winscribe than Greg Allen,” said Matthew Weavers, Winscribe’s Founder ... leader with a wealth of commercial, IT and management ...
(Date:8/28/2014)... Peoria, Illinois (PRWEB) August 29, 2014 ... of feeling tired all the time, twenty percent of ... to interfere with their daily life. Adrenal Fatigue is ... if you have more of the classic symptoms. Tasks ... flairs up over things that previously didn’t cause irritation, ...
Breaking Medicine News(10 mins):Health News:North York Dental Provides Dental Services to Busy Professionals 2Health News:Sport and Spine Rehab’s CEO Presents at the Florida Chiropractic Association National Convention and Expo 2014 2Health News:Relax this Labor Day Weekend with Great Savings on Easy-Install, Do-It-Yourself Drinking and Whole House Water Filters 2Health News:Winscribe Names Greg Allen as CEO 2Health News:Peoria AlignLife Clinics Focus on Community Education 2
... between tests, researchers say , THURSDAY, Oct. 4 (HealthDay ... DNA testing enables earlier detection of lesions that lead ... women could go longer between screenings, say researchers at ... study included more than 17,000 women ages 29 to ...
... Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... to retire next year.,Renton, 60, will remain chairman of ... the company is initiating a search for a successor. ... to the newly created,position of executive vice president & ...
... Inc.,(Nasdaq: ANSV ) today announced that it ... review the company,s launch and commercialization,plans for Zingo(TM) ... will take place on Friday,October 12, 2007 from ... York City. To,access the live audio broadcast or ...
... the,November 2006 Rand Corp. study, health care provided ... a year nationally and that 68,percent of illegal ... of millions of newcomers, U.S.-born and foreign-born relatives ... to the U.S. population.,They will also consume energy, ...
... ANA, Calif., Oct. 4 More than 35,million children ... the streets in,costume this Halloween. Although hours of planning ... people fail to consider,the importance of security. "Today, most ... in a sealed wrapper and safe to eat," says ...
... ... organizations, ST. PAUL, Minn., Oct. ... announced today it has,achieved URAC Pharmacy Benefit Management (PBM) accreditation. ... practices, promote quality improvement and protect and,empower consumers. Prime began its ...
Cached Medicine News:Health News:Gene-Based Screen Spots Cervical Cancer Earlier 2Health News:Onyx Pharmaceuticals Announces Management Changes 2Health News:Onyx Pharmaceuticals Announces Management Changes 3Health News:Anesiva to Unveil Zingo(TM) Commercialization Plans 2Health News:Message for Activists at Latino National Congreso Convention: Amnesty Will Exacerbate National Problems and Turn the U.S. into Another Mexico 2Health News:Safety Tips for a Fun and Spooky Halloween 2Health News:Prime Therapeutics Announces URAC Accreditation 2
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Medicine Products: